Skip to main content

8 Result(s)

within R.A.A. Mathôt Remove this filter

and

  1. Article

    Open Access

    Are higher antidepressant plasma concentrations associated with fall risk in older antidepressant users?

    To explore the association between antidepressant plasma concentrations and fall risk in older users.

    A. C. Pronk, E. P. van Poelgeest, L. J. Seppala… in European Geriatric Medicine (2023)

    Download PDF (448 KB) View Article

  2. Article

    Open Access

    In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients

    Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become available. Prophylactic dosing of EHL-FIX concentrates can be o...

    T. Preijers, M. W. F. van Spengler, K. Meijer… in European Journal of Clinical Pharmacology (2022)

    Download PDF (1419 KB) View Article

  3. No Access

    Article

    The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy

    We investigated the relationship between cyclosporine exposure and the presence of cyclosporine-related side effects and assessed the advantage of the cyclosporine concentration 2 h post-dose (C2) over pre-dose c...

    D. A. Hesselink, T. van Dam, H. J. Metselaar, A. H. M. M. Balk… in Transplant International (2004)

  4. Article

    Open Access

    Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

    To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetics of topotecan administered as a 30-min intravenous (i.v.) infusion over 5 days in combination with a 1-h i.v. infusi...

    T Kerbusch, G Groenewegen, R A A Mathôt, V M M Herben… in British Journal of Cancer (2004)

    Download PDF (207 KB) View Article

  5. No Access

    Article

    Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology

    The application of pharmacokinetic (PK) and pharmacodynamic (PD) modeling in drug development has emerged during the past decades and it is has been suggested that the investigation of PK–PD relationships duri...

    Ch. van Kesteren, R.A.A. Mathôt, J.H. Beijnen… in Investigational New Drugs (2003)

  6. No Access

    Article

    Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects

    In this study we investigated the relationship between the pharmacokinetics and the cardiovascular and electroencephalogram (EEG) effects of three adenosine agonists with differing lipophilicity. Conscious nor...

    E. A. van Schaick, C. Kulkarni… in Naunyn-Schmiedeberg's Archives of Pharmaco… (1997)

  7. No Access

    Article

    Abstracts of papers Pharmacological Meeting

    W. A. Bax, P. R. Saxena, Gerreke Ph. Biewenga, Jan de Jong… in Pharmacy World and Science (1993)

  8. No Access

    Article

    Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives

    A new approach to preclinical pharmacodynamic investigations is presented which allows, in addition to information on the nature of the pharmacological properties of new chemical entities, also important quant...

    M. Danhof, J. W. Mandema, A. Hoogerkamp… in European Journal of Drug Metabolism and Ph… (1993)